DiaMedica TherapeuticsDMAC
Market Cap: $173M
About: DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
Employees: 19
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
15% more capital invested
Capital invested by funds: $13M [Q1] → $14.9M (+$1.93M) [Q2]
1.03% more ownership
Funds ownership: 12.36% [Q1] → 13.39% (+1.03%) [Q2]
0% more funds holding
Funds holding: 32 [Q1] → 32 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
0% more call options, than puts
Call options by funds: $8K | Put options by funds: $8K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Oppenheimer Francois Brisebois 60% 1-year accuracy 18 / 30 met price target | 49%upside $6 | Outperform Reiterated | 16 Aug 2024 |